What is Delvitech?
Delvitech operates within the life sciences sector, specializing in the design and manufacturing of advanced analytical instruments crucial for pharmaceutical and biotechnology quality control. Their flagship Delvi Diagnostics Platform offers real-time measurement of critical quality attributes (CQAs) in drug products, such as protein aggregation and particle size distribution. This technology empowers pharmaceutical manufacturers and contract development organizations (CDOs) to conduct rapid, automated quality testing throughout drug development and manufacturing processes, aligning with the FDA's Process Analytical Technology (PAT) initiative. By integrating optical measurement techniques with automated sample handling and data analytics, Delvitech enhances drug product quality and manufacturing efficiency.
How much funding has Delvitech raised?
Delvitech has raised a total of $40M across 1 funding round:
Series B
$40M
Series B (2025): $40M with participation from CreAdd and EGS Beteiligungen
Key Investors in Delvitech
CreAdd
CreAdd is an entity focused on creating valuable visual content for businesses, leveraging specialists from various industries to enhance brand image through compelling imagery.
EGS Beteiligungen
EGS Beteiligungen AG is a subsidiary of Ernst Göhner Stiftung, dedicated to long-term investments in Swiss-related companies, with a focus on capital preservation and ethical, sustainable profitability, including growth financing for late-stage technology startups.
What's next for Delvitech?
The substantial enterprise-level funding positions Delvitech for significant scaling and further innovation in analytical instrumentation. This capital infusion is expected to accelerate product development, expand market reach, and bolster manufacturing capabilities. The strategic investment signals strong confidence from backers in Delvitech's technology and its potential to revolutionize quality control in the pharmaceutical and biotech industries, paving the way for broader adoption and impact.
See full Delvitech company page
